500 mg orally once daily (chronic myeloid leukmia (chronic and accelerated phases and blast crisis with resistance/intolerance to prior therapy)); 400 mg orally once daily (newly diagnosed chronic myeloid leukemia (chronic phase));
94% binding to human plasma proteins in vitro; 96% bound to human plasma proteins in healthy subjects ex vivo